Burning Rock Biotech logo

Burning Rock Biotech(NASDAQ) BNR

Market Cap$140.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-94%
5 Year-91%
1 Year+84%
1 Month+73%
$15.99
-9.30%
-1.64Today
Burning Rock Biotech last closing stock price
MetricPriceDate
Last closeUSD 15.992026-10-01
Burning Rock Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.17%USD 18.002026-09-24
1 month+73.43%USD 9.222026-09-01
3 month+62.83%USD 9.822026-07-02
Year to date-20.65%USD 20.152025-12-31
1 year+84.43%USD 8.672025-10-01
3 year+63.16%USD 9.802023-10-02
5 year-90.58%USD 169.802021-10-01
Since inception-93.51%USD 246.302020-06-12

Burning Rock Biotech Financials at a Glance

Market Cap

$140.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥500.78M

Net Income (TTM)

-CN¥68.05M

EPS (TTM)

-$0.91

P/E Ratio

-17.52

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$15.99

Volume

10

Open

$17.83

Previous Close

$15.99

Daily Range

$15.99 - $18.01

52-Week Range

$6.79 - $41.72

Estimated Earnings Date

Nov 17, 2026

BNR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Burning Rock Biotech

Burning Rock Biotech Limited is a leading provider of diagnostic solutions for cancer therapy selection, headquartered in Guangzhou, China. Established in 2014, the company utilizes next-generation sequencing technology to develop a diverse portfolio of tests aimed at guiding therapeutic decisions for various cancer types.

Products and Services
  • OncoCompass IO: A liquid biopsy test for cancer therapy selection
  • OncoScreen IO: A comprehensive pan-cancer test for tissue samples
  • ColonCore: Assesses microsatellite instability and genetic mutations in gastrointestinal cancers
Growth Outlook
  • Strategic partnerships with major pharmaceutical companies enhance market reach
  • Increasing demand for personalized medicine drives growth in diagnostic testing
  • Expansion into new markets is anticipated to boost revenue streams
Financial Highlights
  • Q2 2026 revenue of 134.91 million CNY, up from 107.94 million CNY in Q1 2026
  • Gross profit margin remains strong at 72.58% in Q2 2026
  • Cash and cash equivalents totaled 419.26 million CNY as of June 30, 2026
Burning Rock Biotech Limited operates across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company is committed to advancing cancer diagnostics through innovative technologies and strategic collaborations. Recent financial performance indicates a positive trend, with a notable increase in revenue from Q1 to Q2 2026, reflecting the growing demand for its diagnostic solutions. The strong gross profit margin underscores the company's operational efficiency, while a solid cash position provides a buffer for future investments and growth initiatives. As the healthcare landscape evolves, Burning Rock is well-positioned to capitalize on the increasing focus on personalized medicine and targeted therapies.
AI Generated • Sep 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

667

CEO

Yu Sheng Han, MBA

Website

www.brbiotech.com

Headquarters

Guangzhou, GD 510005, CN

BNR Financials

Key Financial Metrics (TTM)

Gross Margin

74.55%

Operating Margin

-12.99%

Net Income Margin

-13.59%

Return on Equity

-12.97%

Return on Capital

-9.48%

Return on Assets

-9.06%

Earnings Yield

-5.71%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$140.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.79M

Volume

10

Avg. Volume

29.77K

Financials (TTM)

Gross Profit

CN¥373.34M

Operating Income

-CN¥65.03M

EBITDA

-CN¥42.24M

Operating Cash Flow

-CN¥12.22M

Capital Expenditure

-CN¥5.25M

Free Cash Flow

-CN¥17.47M

Cash & ST Invst.

CN¥419.26M

Total Debt

CN¥45.13M

Burning Rock Biotech Performance Analysis

Burning Rock Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 83,644,4806.2%
20232023-12-31CNY 75,855,022-9.3%
20242024-12-31CNY 71,673,625-5.5%
20252025-12-31CNY 75,060,4304.7%
Burning Rock Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-11.4%
Q42025-12-31-4.0%
Q12026-03-31-14.5%
Q22026-06-3025.0%
Burning Rock Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -13.8817.1%
20232023-12-31CNY -9.01-35.1%
20242024-12-31CNY -4.68-48.1%
20252025-12-31CNY -0.72-84.5%
Burning Rock Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-73.3%
Q42025-12-315.8%
Q12026-03-31-15.6%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥134.91M

-9.2%

Gross Profit

CN¥97.92M

-9.4%

Gross Margin

72.58%

N/A

Market Cap

$140.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$210.62K

N/A

Employees

667

N/A

Net Income

-CN¥18.43M

-90.0%

EBITDA

-CN¥15.75M

-564.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥419.26M

-7.4%

Total Debt

CN¥45.13M

+15.3%

Accounts Receivable

CN¥182.61M

-10.8%

Inventory

CN¥34.14M

-40.9%

Long Term Debt

CN¥23.75M

+20.7%

Short Term Debt

CN¥21.38M

+9.9%

Return on Assets

-9.06%

N/A

Return on Invested Capital

-12.20%

N/A

Free Cash Flow

-CN¥22.35M

+49.6%

Operating Cash Flow

-CN¥22.35M

+49.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PMNProMIS Neurosciences, Inc.
$9.38-13.55%
EKSOEkso Bionics Holdings, Inc.
$15.90-9.86%
AYTUAytu BioPharma, Inc.
$2.09-2.34%
ADVBAdvanced Biomed Inc. Common Stock
$6.91+10.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$31.76-3.99%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$153.69+3.94%
NKENike
$35.15-0.71%
TQQQProShares Trust - ProShares UltraPro Qqq
$78.73+0.90%

Questions About BNR

What is the current price of Burning Rock Biotech?

Burning Rock Biotech is trading at $15.99 per share.

What is the 52-week range for Burning Rock Biotech?

Over the past 52 weeks, Burning Rock Biotech has traded between $6.79 and $41.72.

How much debt does Burning Rock Biotech have?

As of the most recent reporting period, Burning Rock Biotech reported total debt of CN¥6.65M.

How much cash does Burning Rock Biotech have on hand?

Burning Rock Biotech reported CN¥61.77M in cash and cash equivalents in its most recent financial results.

What is Burning Rock Biotech’s dividend yield?

Burning Rock Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services